Cyxone AB
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
Market Cap & Net Worth: Cyxone AB (CYXO)
Cyxone AB (ST:CYXO) has a market capitalization of $601.80K (Skr6.75 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #38380 globally and #630 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyxone AB's stock price Skr0.02 by its total outstanding shares 375057984 (375.06 Million).
Cyxone AB Market Cap History: 2016 to 2025
Cyxone AB's market capitalization history from 2016 to 2025. Data shows change from $242.39 Million to $601.80K (-49.57% CAGR).
Cyxone AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyxone AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.65x
Cyxone AB's market cap is 0.65 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $242.39 Million | $21.00K | -$4.16 Million | 11542.40x | N/A |
| 2018 | $85.76 Million | $1.00K | -$15.43 Million | 85756.07x | N/A |
| 2019 | $140.08 Million | $26.57K | -$35.17 Million | 5272.50x | N/A |
| 2020 | $141.76 Million | $-26.00K | -$49.00 Million | -5452.18x | N/A |
| 2022 | $17.08 Million | $6.40 Million | -$42.47 Million | 2.67x | N/A |
| 2023 | $3.36 Million | $5.15 Million | -$22.99 Million | 0.65x | N/A |
Competitor Companies of CYXO by Market Capitalization
Companies near Cyxone AB in the global market cap rankings as of March 19, 2026.
Key companies related to Cyxone AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Cyxone AB Historical Marketcap From 2016 to 2025
Between 2016 and today, Cyxone AB's market cap moved from $242.39 Million to $ 601.80K, with a yearly change of -49.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr601.80K | 0.00% |
| 2024 | Skr601.80K | -82.07% |
| 2023 | Skr3.36 Million | -80.35% |
| 2022 | Skr17.08 Million | -70.93% |
| 2021 | Skr58.78 Million | -58.54% |
| 2020 | Skr141.76 Million | +1.19% |
| 2019 | Skr140.08 Million | +63.35% |
| 2018 | Skr85.76 Million | -77.00% |
| 2017 | Skr372.78 Million | +53.79% |
| 2016 | Skr242.39 Million | -- |
End of Day Market Cap According to Different Sources
On Jan 2nd, 2026 the market cap of Cyxone AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $601.80K USD |
| MoneyControl | $601.80K USD |
| MarketWatch | $601.80K USD |
| marketcap.company | $601.80K USD |
| Reuters | $601.80K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.